Clinical Trials Browser

Phase 3 × Triple Negative Breast Neoplasms × Albumin-Bound Paclitaxel × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT04251533 2026-05-11

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Breast

Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

623 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Breast

Triple Negative Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Phase 3 Active not recruiting

443 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02819518 2024-11-27

KEYNOTE-355

Phase 3 Completed

882 enrolled 41 charts 1 FDA

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02620280 2024-03-06

NeoTRIPaPDL1

Phase 3 Completed

278 enrolled

Breast

Carcinoma, Ductal, Breast, Triple Negative Breast Neoplasms

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Phase 3 Completed

902 enrolled 27 charts 1 FDA

Breast

Triple Negative Breast Neoplasms

Clinical Trials

TroFuse-011

EPIK-B3

ASCENT-03

EL1SSAR

ASCENT-04

KEYNOTE-355

NeoTRIPaPDL1

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)